Cost Minimization Study between Intravenous Rituximab (R-IV) vs Subcutaneous Rituximab (R-SC) in Thai Patients with Diffused Large B-CELL Lymphoma (DLBCL)- A Simulation of Electronic Health Record (E-HR) and Evidence Synthesis
Abstract
Authors
K Chansung C Sirijerachai N Teawtrakul